Investor Relations

Life science company focused on
solving Duchenne muscular dystrophy

Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (Duchenne). Founded by those touched by the disease, Solid is a center of excellence for Duchenne, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential.

Stock Information

NASDAQ SLDB

Copyright West LLC.
Minimum 15 minutes delayed.
Press Releases
  • Jan 06

    Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot , Chief Executive Officer, President and Co-Founder, will present

    Read More
  • Dec 11

    Solid Biosciences Announces $90 Million Private Placement

    CAMBRIDGE, Mass. , Dec. 11, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has entered into a securities purchase agreement with a select group of

    Read More
View All News
Events
  • Jan 14

    39th Annual J.P. Morgan Healthcare Conference

    Listen to Webcast
  • Nov 5

    Solid Biosciences Third Quarter 2020 Financial Results Call

    View Webcast
View All Events